ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1346

Post-Traumatic Stress Disorder, Depression, Anxiety and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis

Luke Desilet1, Joshua Baker 2, Bryant England 3, Kaleb Michaud 1, Jennifer Barton 4 and Ted Mikuls 5, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, 4VA Portland Health Care System & Oregon Health & Science University, Portland, OR, 5VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: comorbidity and drug treatment, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Session Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Treatments, Outcomes, & Measures

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Post-traumatic stress disorder (PTSD) is associated with worse outcomes among U.S. Veterans with rheumatoid arthritis (RA) in addition to reduced medication adherence in other chronic disorders. This study examined the association between PTSD and DMARD discontinuation, accounting for comorbidity and other potential confounders that may impact this relationship.

Methods: VA administrative data were used to define unique dispensing episodes of methotrexate (MTX), self-injectable TNF inhibitors (TNFi), other DMARDs, and prednisone for Veterans with a prior diagnostic code for RA. Discontinuation was defined as a lapse in drug refill >90 days. Patient characteristics and diagnosis codes were linked to treatment courses. Patient characteristics were analyzed based on the first dispensing episode of each unique DMARD. Some patients switched TNFi’s over time and thus accounted for multiple dispensing episodes. Diagnosis codes (using a “lifetime” lookback) were used to delineate RA patients into 3 mutually exclusive groups: PTSD (with or without depression/anxiety), depression and/or anxiety without PTSD, and none of the aforementioned diagnoses. Multivariate Cox proportional hazards models were used to evaluate associations between psychiatric diagnoses and time to DMARD discontinuation. Covariates included age, sex, race (Black vs. White), calendar year (2005-2009 vs. 2010-2014), BMI, other DMARDs, Rheumatic Disease Comorbidity Index (RDCI), CRP, anti-CCP status, RA duration >5 years, diabetes, hypertension, CHF, history of malignancy, and current smoking status.

Results: There were 15,082 dispensing episodes of MTX in 15,082 unique patients and 8,412 dispensing episodes for TNFi in 7,092 unique RA patients. Patients were predominantly Caucasian (74% MTX, 77% TNFi) and male (88% MTX, 87% TNFi). Median drug survival was 1.30 years (95% CI 1.27-1.35) for MTX and 1.18 years (95% CI 1.13-1.24) for TNFi. Comorbid PTSD was seen in 20% of those initiating MTX and 22% of those initiating TNFi. Depression and/or anxiety (without PTSD) was seen in 23% of those initiating MTX and 27% of those initiating TNFi. After adjusting for covariates, PTSD was associated with a greater likelihood of discontinuing both MTX [HR 1.12 (1.07,1.18) p< 0.001; Figure 1] and TNFi [HR 1.16 (1.09,1.23) p< 0.001; Figure 2]. Risk of discontinuation in depression/anxiety without PTSD was comparable to that seen in PTSD for both MTX [HR 1.12 (1.07,1.17) p< 0.001] and TNFi [HR 1.14 (1.08,1.21) p< 0.001].

Conclusion: Veterans with RA and a diagnosis of PTSD, depression, or anxiety discontinued DMARDs sooner than those without these diagnoses, even after accounting for a number of other factors.  Rates of discontinuation were similar for those with PTSD compared to those with depression and/or anxiety alone and were similar between MTX and TNFi. PTSD, anxiety, and depression may contribute to lower persistence of RA therapy due to non-adherence, apparent lack of response, or a greater incidence of adverse events.


luke_KM_adjusted_mtx_survival

Figure 1. Methotrexate drug survival
-Note that PTSD and Anxiety/Depression groups have significant overlap in this figure-


luke_KM_adjusted_TNF_survival

Figure 2. TNF inhibitor drug survival
-Note that PTSD and Anxiety/Depression groups have significant overlap in this figure-


Disclosure: L. Desilet, None; J. Baker, Bristol-Myers Squibb, 2, 5, Burns-White LLC, 5; B. England, None; K. Michaud, FORWARD, The National Databank for Rheumatic Diseases, 3, Pfizer, 2, Pfizer & Rheumatology Research Foundation, 2, Rheumatology Research Foundation, 2, University of Nebraska Medical Center, 3; J. Barton, None; T. Mikuls, BMS, 2, Horizon, 2.

To cite this abstract in AMA style:

Desilet L, Baker J, England B, Michaud K, Barton J, Mikuls T. Post-Traumatic Stress Disorder, Depression, Anxiety and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/post-traumatic-stress-disorder-depression-anxiety-and-persistence-of-methotrexate-and-tnf-inhibitors-in-patients-with-rheumatoid-arthritis/. Accessed July 1, 2022.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-traumatic-stress-disorder-depression-anxiety-and-persistence-of-methotrexate-and-tnf-inhibitors-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies